Quadrature Capital’s Pacira BioSciences PCRX Stock Holding History

Quadrature Capital’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-19,266	Closed	-$435K	–	1945
2026 Q1	$435K	Buy	+19,266	New	+$428K	0.01%	841

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Quadrature Capital's PCRX Position: Q2 2026 in Review

Quadrature Capital sold out of Pacira BioSciences (PCRX) in Q2 2026, closing a stake of 19,266 shares — an estimated $435K sold.

Quadrature Capital first reported a position in PCRX in Q1 2026 and held it in 1 quarter. The position peaked at $435K in Q1 2026. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

Quadrature Capital reported no remaining Pacira BioSciences position as of Q2 2026 after selling out during the quarter.
Quadrature Capital sold 19,266 Pacira BioSciences shares in Q2 2026, an estimated $435K.
Quadrature Capital first reported a position in Pacira BioSciences in Q1 2026 and held it in 1 quarter.
Quadrature Capital's Pacira BioSciences position peaked at $435K in Q1 2026.
253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Quadrature Capital's 13F filing for Q2 2026, filed 7 Aug 2026.